Table 2.

Endpoints of the SUPERIOR study

	Placebo (n = 47)	Meropenem (n = 44)	% Difference (95% CIs)	Odds ratio (95% CI s)	p value
Primary endpoint: early worsening, n (%)	19 (40.4)	7 (15.9)	24∙5 (5.9 to 40.8)	0.28 (0.10 to 0.76)	0.011
Secondary endpoints
At least 2-point SOFA increase the first 24 h, n (%)	10 (21.3)	2 (4.5)	16∙7 (2.7 to 30.8)	0.18 (0.04 to 0.86)	0.028
Early worsening per quartile of the admission SOFA score, n/patients at the respective quartile (%)
SOFA = 0-1 points	5/15 (33.3)	0/6 (0)	33.3 (− 0.09 to 0.58)	*	0.262
SOFA = 2–3 points	6/10 (60.0)	7/20 (35.0)	25.0 (− 0.11 to 53.7)		0.255
SOFA = 4 points	5/12 (41.7)	0/8 (0)	41.7 (2.2 to 68.1)	*	0.055
SOFA > 4 points	3/10 (30∙0)	0/10 (0)	30.0 (− 7.7 to 60.3)	*	0.211
Resolution of infection, n (%)	29 (61.7)	37 (84.1)	22.4 (4.0 to 38.7)	3∙28 (1.21 to 8.91)	0.020
Time to infection resolution, days, median (Q1-Q3)	13.0 (9 to 60)	12 (8 to 15.8)	NA	NA	0.018
7-day mortality, n (%)	2 (4.3)	0 (0)	4.3 (− 4.3 to 14.3)	*	0.494
28-day mortality, n (%)	8 (17∙0)	4 (9.1)	7∙9 (− 6.6 to 22.2)	0.49 (0.14 to 1.75)	0.357
60-day mortality, n (%)	11 (23.4)	8 (18.2)	5.2 (− 11.7 to 21.5)	0.73 (0.26 to 2.02)	0.611
90-day mortality, n (%)	15 (31.9)	9 (20.5)	11.5 (− 6.7 to 28.5)	0.55 (0.21 to 1.43)	0.242
New infections the first 7 days, n (%)	4 (8.5)	3 (6.8)	1.7 (− 10.8 to 13.9)	0.79 (0.17 to 3.73)	1.000
New infections the first 60 days, n (%)	18 (38.3)	14 (30.2)	6.5 (− 12.8 to 25.0)	0.69 (0.29 to 2.68)	0.507
Change of antibiotics, n (%)	24 (51.1)	18 (40.9)	10.2 (− 10 to 29.2)	0.66 (0.29 to 1.52)	0.402
Duration of hospitalization, days, median (range)	8 (5 to 14)	11 (6.3 to 17)	NA	NA	0.372

*Cannot be calculated because one value is zero

n Number of patients, SD standard deviation, SOFA Sequential Organ Failure